What Does the Published Research Say About MOTS-C?

What This Article Covers

This article summarizes published research on MOTS-C for technical review. It separates direct human evidence, review-level context, and animal or mechanistic work so the reader can see what has actually been tested before seeing the limitations.

MOTS-c is a mitochondrial-derived peptide encoded by the mitochondrial genome. The supplied synthesis evidence set includes 10 PubMed-indexed citations (one review). Evidence set-level notes emphasize that the evidence base is driven mainly by preclinical/mechanistic work. While the evidence set classifies a subset of citations as “clinical,” it provides little or no study-design or endpoint detail. Accordingly, we separate evidence set-classified human signals from review context and preclinical/mechanistic findings and avoid extrapolating beyond the specific disease contexts suggested by titles. Where titles are clearly mechanistic, we treat those items as preclinical even if evidence set classifications appear inconsistent.

Bottom Line

Based on this evidence set, MOTS-c research is predominantly preclinical/mechanistic. The evidence set classifies a limited set of citations as clinical signals, but without study-design or endpoint details, any conclusions must remain narrowly constrained to the populations and outcomes indicated by their titles. The strongest supported conclusions should stay anchored to the studied human population, endpoint, and disease context. The evidence set does not establish dosing, safety profiles, generalized anti-aging effects, or broad clinical utility.

What Was Tested in Humans?

No controlled human intervention data were identified in the available evidence set used for this draft. That does not mean the compound has no research interest; it means human outcome claims should not be made from this article’s source base.

What Do Reviews and Evidence Syntheses Add?

• A narrative review discusses MOTS-c in diabetes and aging-related diseases [pubmed:36824008]. This is background context and does not constitute primary clinical efficacy evidence within this evidence set.

What Did Animal and Mechanistic Studies Show?

The available evidence set should be interpreted carefully when it includes animal, cellular, formulation, or mechanistic findings. Those findings can explain why researchers study the compound, but they should not be presented as established human outcomes.

How the Evidence Fits Together

The practical reading for MOTS-C is evidence hierarchy. Human studies, when present, carry the most weight, but only for the exact population, route, comparator, and endpoint studied. Reviews can help map the field, and animal or mechanistic studies can explain biological plausibility, but neither should be used to leap beyond the human evidence.

What Is Not Established

• Broad human efficacy for MOTS-C is not established by this article.
• Animal, cellular, or review-level findings should not be converted into human-use claims.
• Dosing, administration, treatment, diagnostic, or veterinary-use guidance is outside the scope of KRL materials.

Research-Use Boundary

This article summarizes published research and regulatory-source discussion for technical review. It is not medical advice, not a dosing guide, and not a recommendation for human or veterinary use. KRL materials are sold for research use only and are not for diagnostic, therapeutic, or administration purposes.

Selected Sources

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. PubMed: https://pubmed.ncbi.nlm.nih.gov/25738459/
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. PubMed: https://pubmed.ncbi.nlm.nih.gov/34798268/
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. PubMed: https://pubmed.ncbi.nlm.nih.gov/39321430/
• MOTS-c reduces myostatin and muscle atrophy signaling. PubMed: https://pubmed.ncbi.nlm.nih.gov/33554779/
• The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. PubMed: https://pubmed.ncbi.nlm.nih.gov/29983246/
• The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism. PubMed: https://pubmed.ncbi.nlm.nih.gov/38790718/
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection. PubMed: https://pubmed.ncbi.nlm.nih.gov/37788894/
• Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases. PubMed: https://pubmed.ncbi.nlm.nih.gov/36824008/
• The mitochondrial-derived peptide MOTS-c suppresses ferroptosis and alleviates acute lung injury induced by myocardial ischemia reperfusion via PPARγ signaling pathway. PubMed: https://pubmed.ncbi.nlm.nih.gov/37290680/
• The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression. PubMed: https://pubmed.ncbi.nlm.nih.gov/38206815/

Related KRL Resources

• Research Compound Catalog
• Technical Products
• FAQ